Gabriele Ghirlanda, Global Access and Value Chief at Angelini Pharma, talks about his work and explains at what stage of drug development he intervenes, who are the key stakeholders with whom he interfaces, both inside and outside the company. He describes, as well, the process that leads pharmaceutical companies and Health Technology Assessment (HTA) bodies to determine the value of a drug and its price and how he can contribute to the aims of Angelini Parma to be “Every step closer” to people.